

CTI BIOPHARMA CORP  
Form FWP  
December 04, 2015

**Issuer Free Writing Prospectus dated December 4, 2015**

**Filed Pursuant to Rule 433**

**Registration No. 333-200452**

**(Relating to the Preliminary Prospectus Supplement dated December 3, 2015  
and the Prospectus dated December 8, 2014)**

**55,000 Shares of Series N-2 Preferred Stock**

Issuer:	CTI BioPharma Corp.
Symbol:	CTIC
Shares offered:	55,000 shares of Series N-2 Preferred Stock (convertible into approximately 50.0 million shares of common stock at the initial conversion price)
Price per share to the public:	\$1,000
Initial conversion price:	\$1.10
Total public offering price:	\$55,000,000
Pricing date:	December 4, 2015
Closing date:	On or about December 9, 2015
CUSIP:	12648L 502
Conversion:	Except to the extent limited by the beneficial ownership limitation described below, each share of Series N-2 Preferred Stock can be converted at the holder's option at any time after issuance into the number of shares of common stock determined by dividing the aggregate stated value of the Series N-2 Preferred Stock of \$1,000 per share to be converted by the conversion price then in effect,

In addition, on the first to occur of:

- i. the 30th day after the original issuance date of the Series N-2 Preferred Stock,
  
- ii. the date on which 5,000 or less shares of Series N-2 Preferred Stock remain outstanding, or
  
- iii. the adoption by our board of directors of a resolution that it intends to adopt an amendment to our articles of incorporation without shareholder approval to effect a reverse stock split with respect to our common stock in order to achieve compliance with the listing rules of The NASDAQ Capital Market or for other good faith business reasons (in each case, an Automatic Conversion Date ),

all outstanding shares of Series N-2 Preferred Stock, except to the extent limited by the beneficial ownership limitation described below, shall automatically convert into the number of shares of our common stock determined by dividing the aggregate stated value of the Series N-2 Preferred Stock being converted by the conversion price then in effect.

Notwithstanding the beneficial ownership limitation described below, any shares of Series N-2 Preferred Stock that were not converted into shares of our common stock on or prior to the Automatic Conversion Date shall automatically convert into shares of our common stock on the earlier of (i) the date on which the conversion of such shares of Series N-2 Preferred Stock would no longer result in beneficial ownership that would exceed the beneficial ownership limitation described below and (ii) the 91st day after the original issuance date of the Series N-2 Preferred Stock.

Beneficial ownership limitation:

No shares of Series N-2 Preferred Stock shall be convertible by a holder to the extent such conversion would result in the holder and its affiliates beneficially owning more than 19.99% of our common stock then outstanding,

Underwriters:

Piper Jaffray & Co. is acting as sole book-running manager for the offering. Ladenburg Thalmann & Co. Inc. is acting as lead manager and Roth Capital Partners, LLC is acting as co-manager for this offering.

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may obtain these documents for free by visiting EDGAR on the SEC Web site at [www.sec.gov](http://www.sec.gov). Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus upon request by calling toll-free (800) 747-3924. Any investor purchasing securities in this offering is exclusively responsible for any disclosure obligations it may have as a result of such purchasing pursuant to Italian law.